We are excited to announce that BrightInsight has been named Frost & Sullivan’s 2023 Global Company of the Year in the IoT healthcare solutions industry.
It is humbling to receive this award from one of the top industry analyst firms in the world. Each year, Frost & Sullivan presents a Company of the Year Award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. Industry analysts compare market participants and measure performance through in-depth interviews, analyses and extensive secondary research to identify best practices in the industry.
It is an honor to be recognized as the leading software-as-a-service (SaaS) provider accelerating compliant digital health innovation and adoption in biopharma and medtech. BrightInsight has invested more than $100 million in building a robust, scalable infrastructure that is currently deployment-ready in 64 countries and counting. We are also proud to partner with many of the world’s leading pharma and medtech companies to rapidly build and scale compliant companion apps, algorithms, analytics dashboards and software as a medical device (SaMDs) to support the patient journey.
“BrightInsight provides a proven unified solution that ensures speed, compliance and scalability. BrightInsight’s modular platform and configurable Disease Management Solution enable biopharma and medtech customers to get an app or Software as a Medical Device (SaMD) to market quickly and scale over time as they see results, creating cost efficiencies. BrightInsight remains a trusted partner, earning a reputation for offering the overall best in the healthcare IoT market.”
– Amartya Bose, Industry Analyst at Frost & Sullivan
Our customers—which include leading global biopharma, medtech and in vitro diagnostics (IVD) companies such as Sanofi, Roche, Novo Nordisk, CSL Behring and bioMérieux—are realizing the value of digital as a way to differentiate their therapies, identify and engage patients, and increase brand awareness and loyalty. Future-looking biopharma companies are meeting the demands of patients who want personalized digital therapy-support tools while addressing specific patient pain points, as well as brand challenges.
Through these next-generation digital tools, our customers enable personalized care, improved outcomes, and increase communication between providers and patients. They are creating patient apps that help make life easier for their patients and increase first-fill rates, therapy adherence and persistence and brand loyalty.
We built the BrightInsight Platform from the ground up with compliance and scalability at the forefront to provide our biopharma and medtech customers an efficient and de-risked way to iterate, launch and expand their patient app offerings over time. We’ve completed 18 SaMD projects across diverse therapy areas and recently supported a customer in achieving its CE-mark approval for a companion patient app.
We’re excited to be recognized for leading this industry to where it is now and even more thrilled to lead it into the future.
For more, read the full report: BrightInsight, Inc. Receives the 2023 Company of the Year Award